Intranasal vasotocin decreases cerebrospinal fluid 5-HIAA levels in man

A single dose (10 ng/kg) of the nonapeptide arginine vasotocin (AVT) administered intranasally to healthy young men, significantly decreased 5-HIAA levels in the lumbar cerebrospinal fluid (CSF) 8 hr after its administration. So far, this represents the smallest amount of an active substance able to alter CSF 5-HIAA levels in man. It is suggested that the decrease of CSF 5-HIAA levels after AVT administration reflects an AVT-induced reduction of the brain 5-HT turnover.